Anti-Nuclear Antibody (ANA) by IFA - End Point Titer
Understanding Anti-Nuclear Antibody (ANA) by IFA - End Point Titer
What is Anti-Nuclear Antibody (ANA) by IFA - End Point Titer?
An Anti-Nuclear Antibody (ANA) by IFA - End Point Titer test helps to identify antinuclear antibodies (ANA) in the blood. These antibodies often attack your body's own tissues specifically targeting each cell's nucleus. This test helps diagnose autoimmune disorders such as lupus, rheumatoid arthritis, scleroderma, and Sjogren’s syndrome.
An Anti-Nuclear Antibody (ANA) by IFA - End Point Titer test helps to detect the antibodies that specifically target components within the cell nucleus. The nucleus of the cell houses the genetic material and is central to cellular function, making antibodies against it particularly significant. This test is instrumental in identifying various autoimmune disorders, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Scleroderma, etc.
While an Anti-Nuclear Antibody (ANA) by IFA - End Point Titer test can't confirm a specific diagnosis, it serves to rule out certain diseases. A positive result prompts further testing for specific antinuclear antibodies, some of which may be associated with particular diseases. Most individuals may have a minor percentage of ANA in their blood but having too much of it can be a sign of an autoimmune disease.
An Anti-Nuclear Antibody (ANA) by IFA - End Point Titer test conducted through the Immunofluorescence Assay (IFA) method, is one of the most sensitive screening tests for detecting ANAs. In this method, fluorescent dyes are used to detect antibodies. It provides information about the part of the cell nucleus which is being targeted by the autoantibodies Although known for its sensitivity, it is a complex method.
An Anti-Nuclear Antibody (ANA) by IFA - End Point Titer test is typically suggested when a doctor suspects an autoimmune disorder due to symptoms such as joint pain, fatigue, skin rashes, light sensitivity, or inflammation. Also, it may be advised if there are risk factors such as aging, obesity, and a family history of autoimmune diseases.
Generally, no special preparations are needed for this test. However, it's advised to inform your doctor about any medications or supplements that you are taking, as certain medications may affect the test results. Additionally, telling a detailed medical history and discussing symptoms can help the doctor correlate the clinical and laboratory findings.
The test results may vary depending on various factors like age, medical history, and certain risk factors among others. Abnormal test results require an expert interpretation; therefore, never try to self-medicate at home based solely on these results, and always consult a doctor for a proper understanding of the test results. The insights from this test help the doctor tailor an appropriate treatment plan.
What is Anti-Nuclear Antibody (ANA) by IFA - End Point Titer used for?
An Anti-Nuclear Antibody (ANA) by IFA - End Point Titer test is done:
-
To detect autoimmune disorders such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), etc.
-
When individuals exhibit symptoms such as joint pain, fatigue, skin rashes, inflammation, etc, associated with certain autoimmune conditions.
-
To identify the possible presence of autoimmune connective tissue disorders other than SLE such as Polymyositis, Scleroderma, Sjögren's syndrome, etc.
-
To monitor the progression and severity of autoimmune disorders over time.
-
For risk assessment in individuals with a family history of autoimmune conditions.
-
For a comprehensive health evaluation, especially when systemic autoimmune involvement is suspected.
What does Anti-Nuclear Antibody (ANA) by IFA - End Point Titer measure?
An Anti-Nuclear Antibody (ANA) by IFA - End Point Titer test checks for antinuclear antibodies (ANA) in your blood. These antibodies, different from typical ones that fight off invaders in the body, can attach to structures inside the body’s own cell nuclei. If ANAs are present in the blood, it may suggest that your immune system is overly sensitive, causing inflammation against your own tissues and possibly indicating autoimmune diseases.
Interpreting Anti-Nuclear Antibody (ANA) by IFA - End Point Titer results
Interpretations
The appearance of fluorescence is a positive result and indicates the presence of antinuclear antibodies.
The absence of fluorescence is a negative result and indicates the absence of antinuclear antibodies.
Positive results of IFA are expressed in two parts: as titers which are ratios that represent the highest dilution of the blood sample at which antinuclear antibodies were visible, and as the fluorescent pattern seen. Titer value indicates the amount of antinuclear antibodies in the blood, while the pattern of fluorescence indicates different autoimmune diseases.
Some common fluorescence patterns and autoimmune conditions associated with them include:
|
FLUORESCENCE PATTERN |
ASSOCIATED CONDITIONS |
|
Homogenous or diffuse |
SLE, drug-induced lupus, and mixed connective tissue disease |
|
Nucleolar |
Scleroderma or Polymyositis |
|
Speckled |
SLE, Sjögren syndrome, Scleroderma, Polymyositis, Rheumatoid Arthritis, and mixed connective tissue disease |
|
Centromere or peripheral |
Scleroderma and CREST Syndrome (Calcinosis, Raynaud syndrome, Esophageal dysmotility, Sclerodactyly, Telangiectasia) |
Answers to Patient Concerns & Frequently Asked Questions (FAQs) about Anti-Nuclear Antibody (ANA) by IFA - End Point Titer
Frequently Asked Questions about Anti-Nuclear Antibody (ANA) by IFA - End Point Titer
Q. What is an Anti-Nuclear Antibody (ANA) by IFA - End Point Titer test?
Q. Why is an Anti-Nuclear Antibody (ANA) by IFA - End Point Titer test done?
Q. How is an Anti-Nuclear Antibody (ANA) by IFA - End Point Titer test performed?
Q. How often should I get an Anti-Nuclear Antibody (ANA) by IFA - End Point Titer test done?
Q. Is there any risk associated with an Anti-Nuclear Antibody (ANA) by IFA - End Point Titer test?
Q. What do abnormal Anti-Nuclear Antibody (ANA) by IFA - End Point Titer test results indicate?
Q. What factors can affect an Anti-Nuclear Antibody (ANA) by IFA - End Point Titer test results?
Q. What is rheumatoid arthritis (RA)?
Q. What is Systemic Lupus Erythematosus (SLE)?
Q. Can I get an Anti-Nuclear Antibody (ANA) by IFA - End Point Titer at home?
Q. If my Anti-Nuclear Antibody (ANA) by IFA - End Point Titer test results are abnormal, what additional tests might my doctor recommend?
Book a Anti-Nuclear Antibody (ANA) by IFA - End Point Titer test at home near me
References
- Antinuclear Antibody [Internet]. Rochester, NY: University of Rochester Medical Center; [Accessed 22 Dec. 2023]. Available from: https://www.urmc.rochester.edu/encyclopedia/content.aspx?contenttypeid=167&contentid=antinuclear_antibodies
- Rheumatoid Factor - an overview [Internet]. ScienceDirect; [Accessed 22 Dec. 2023]. Available from: https://www.sciencedirect.com/topics/medicine-and-dentistry/rheumatoid-factor
- Overview of Systemic Lupus Erythematosus (Lupus) [Internet]. NIH; Oct. 2022. [Accessed 22 Dec. 2023]. Available from: https://www.niams.nih.gov/health-topics/lupus
- Kumar Y, Bhatia A, Minz RW. Antinuclear antibodies and their detection methods in diagnosis of connective tissue diseases: a journey revisited. Diagn Pathol. 2009 Jan 2;4:1. [Accessed 22 Dec. 2023]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2628865/
- Nosal RS, Superville SS, Amraei R, et al. Biochemistry, Antinuclear Antibodies (ANA) [Updated 2022 Dec 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537071/
- Tešija Kuna A, Đerek L, Drvar V, Kozmar A, Gugo K. Assessment of antinuclear antibodies (ANA): National recommendations on behalf of the Croatian society of medical biochemistry and laboratory medicine. Biochem Med (Zagreb). 2022 Jun 15;31(2):020502. [Accessed 22 Dec. 2023]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047791/
- Grygiel-Górniak B, Rogacka N, Puszczewicz M. Antinuclear antibodies in healthy people and non-rheumatic diseases - diagnostic and clinical implications. Reumatologia. 2018;56(4):243-248. [Accessed 22 Dec. 2023]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142026/
- Li QZ, Karp DR, Quan J, Branch VK, Zhou J, Lian Y, Chong BF, Wakeland EK, Olsen NJ. Risk factors for ANA positivity in healthy persons. Arthritis Res Ther. 2011 Mar 2;13(2):R38. [Accessed 22 Dec. 2023]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132017/
- Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD. Manifestations of systemic lupus erythematosus. Maedica (Bucur). 2011 Oct;6(4):330-6. PMID: 22879850; PMCID: PMC3391953. [Accessed 22 Dec. 2023]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3391953/
Other tests
